Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

"Eli Lilly on Wednesday said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity a"